Wall Street analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to report ($1.22) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Theravance Biopharma’s earnings. The highest EPS estimate is ($1.11) and the lowest is ($1.30). Theravance Biopharma posted earnings per share of ($0.76) in the same quarter last year, which indicates a negative year-over-year growth rate of 60.5%. The business is expected to report its next quarterly earnings report on Wednesday, August 7th.

On average, analysts expect that Theravance Biopharma will report full year earnings of ($4.74) per share for the current financial year, with EPS estimates ranging from ($5.20) to ($4.03). For the next financial year, analysts forecast that the business will report earnings of ($4.27) per share, with EPS estimates ranging from ($5.76) to ($3.28). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover Theravance Biopharma.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by ($0.14). Theravance Biopharma had a negative net margin of 388.61% and a negative return on equity of 2,631.71%. The business had revenue of $5.34 million during the quarter, compared to analyst estimates of $16.45 million.

A number of equities research analysts have recently issued reports on TBPH shares. Cantor Fitzgerald reiterated a “buy” rating and set a $55.00 price objective on shares of Theravance Biopharma in a research note on Friday, April 12th. BidaskClub lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, March 9th. Finally, Zacks Investment Research lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $43.40.

In other Theravance Biopharma news, Director Donal O’connor sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $20.46, for a total value of $81,840.00. Following the completion of the sale, the director now owns 30,244 shares of the company’s stock, valued at $618,792.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 6.60% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Theravance Biopharma by 0.8% during the fourth quarter. BlackRock Inc. now owns 3,863,076 shares of the biopharmaceutical company’s stock worth $98,857,000 after acquiring an additional 29,667 shares during the period. Norges Bank bought a new stake in shares of Theravance Biopharma during the 4th quarter valued at $22,422,000. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 0.8% during the 4th quarter. Northern Trust Corp now owns 550,796 shares of the biopharmaceutical company’s stock valued at $14,095,000 after purchasing an additional 4,274 shares during the period. Geode Capital Management LLC grew its position in Theravance Biopharma by 9.4% during the first quarter. Geode Capital Management LLC now owns 544,029 shares of the biopharmaceutical company’s stock worth $12,333,000 after buying an additional 46,805 shares in the last quarter. Finally, Chescapmanager LLC grew its position in Theravance Biopharma by 1.5% during the fourth quarter. Chescapmanager LLC now owns 414,921 shares of the biopharmaceutical company’s stock worth $10,618,000 after buying an additional 6,000 shares in the last quarter. Institutional investors and hedge funds own 84.75% of the company’s stock.

NASDAQ TBPH opened at $15.95 on Tuesday. Theravance Biopharma has a 52 week low of $15.18 and a 52 week high of $35.48.

About Theravance Biopharma

Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.

See Also: How Short Selling Works

Get a free copy of the Zacks research report on Theravance Biopharma (TBPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.